zimeldine and Nausea

The side effect profile and safety of fluoxetine are reviewed. Side effects reported more frequently with fluoxetine than with tricyclic antidepressants are nausea, nervousness, and insomnia. Anticholinergic side effects are reported less often with fluoxetine. Analysis of adverse experiences leading to discontinuations suggests that this drug has very few serious side effects. There is no evidence that fluoxetine produces a flu-like syndrome or neuropathy similar to that seen with zimelidine. It does not appear to cause phospholipidosis in humans. Fluoxetine appears to have no epileptogenic potential except at extremely high doses. It is usually well tolerated in overdoses.

Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical Trials as Topic; Drug Eruptions; Female; Fluoxetine; Humans; Influenza, Human; Lipidoses; Male; Middle Aged; Nausea; Nervous System Diseases; Patient Dropouts; Phospholipids; Placebos; Propylamines; Psychoses, Substance-Induced; Seizures; Sleep Initiation and Maintenance Disorders; Suicide, Attempted; Vision Disorders; Zimeldine

The side effect profile and safety of fluoxetine are reviewed. Side effects reported more frequently with fluoxetine than with tricyclic antidepressants are nausea, nervousness, and insomnia. Anticholinergic side effects are reported less often with fluoxetine. Analysis of adverse experiences leading to discontinuations suggests that this drug has very few serious side effects. There is no evidence that fluoxetine produces a flu-like syndrome or neuropathy similar to that seen with zimelidine. It does not appear to cause phospholipidosis in humans. Fluoxetine appears to have no epileptogenic potential except at extremely high doses. It is usually well tolerated in overdoses.

Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical Trials as Topic; Drug Eruptions; Female; Fluoxetine; Humans; Influenza, Human; Lipidoses; Male; Middle Aged; Nausea; Nervous System Diseases; Patient Dropouts; Phospholipids; Placebos; Propylamines; Psychoses, Substance-Induced; Seizures; Sleep Initiation and Maintenance Disorders; Suicide, Attempted; Vision Disorders; Zimeldine

The aim of this study was to evaluate the safety of zimeldine, a 5-HT reuptake inhibitor, in the long-term treatment of depressive disorders. The study was an open label, multicentre investigation involving 147 patients who were suffering from depressive illness and who needed long-term anti-depressant treatment. Sixty-five patients completed the intended treatment period of 1 year, 75 terminated prematurely, and 7 are still in the programme. The reasons for termination were mainly ineffectiveness of the drug and adverse reactions. During the long-term treatment the most common emergent symptoms were, in order of decreasing frequency, dizziness, dry mouth, sleep disorders, sweating, tremor, nausea and headache. The side-effects were, however, mild and they generally decreased during the treatment period. No new adverse symptoms were reported. In the long-term treatment group, body weight showed a slight mean decrease. Clinical chemistry and cardiovascular investigations were judged to show no changes of clinical importance. It is concluded that zimeldine was shown to be a safe drug in this 1-year treatment programme of depression.

Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Body Weight; Child; Creatinine; Depressive Disorder; Electrocardiography; Female; Humans; Male; Middle Aged; Nausea; Sleep Wake Disorders; Time Factors; Zimeldine